NCT00814762

Safety of the HIV Vaccine 732462 in HIV Infected Subjects Aged 18 to 55 Years Old

Study to Evaluate the Safety and Reactogenicity of the HIV Vaccine SB732462 in HIV Infected Subjects Aged 18 to 55 Years Old

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to evaluate the safety of GSK Biologicals' investigational HIV vaccine 732462, administered as two doses approximately 1 month apart, in a small group of HIV infected people.

Detailed description

This multicenter observer-blind study will determine the safety and reactogenicity of GSK Biologicals' investigational HIV vaccine 732462 in two sequentially enrolling cohorts of HIV-infected subjects treated with HAART (highly active antiretroviral therapy) and HIV infected treatment naïve subjects, respectively.

Conditions

• AIDS

Interventions

Type	Name	Description
BIOLOGICAL	HIV Vaccine 732462	Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.
BIOLOGICAL	Placebo vaccine	Two doses of placebo, injected intramuscularly, at an interval of approximately one month

Timeline

• Start date: 2009-02-03
• Primary completion: 2010-08-18
• Completion: 2010-08-18
• First posted: 2008-12-25
• Last updated: 2018-06-18

Locations

6 sites across 1 country: Germany